Major therapeutic advances and new perspectives in onco-hematology

被引：7

作者：

Bay, Jacques-Olivier ^{[1
,2
]}

Guieze, Romain ^{[1
,2
]}

Ravinet, Aurelie ^{[1
]}

Lemal, Richard ^{[1
]}

Xhaard, Alienor ^{[3
]}

Bailly, Sebastien ^{[1
]}

Molucon-Chabrot, Cecile ^{[1
]}

Hermet, Eric ^{[1
]}

Biau, Julian ^{[4
]}

Verrelle, Pierre ^{[4
]}

de latour, Regis Peffault ^{[3
]}

Tournilhac, Olivier ^{[1
,2
]}

机构：

[1] CHU Clermont Ferrand, Serv Hematol Clin Adulte & Therapie Cellulaire, F-63003 Clermont Ferrand 01, France

[2] Univ Auvergne, EA7283, CIC501, F-63000 Clermont Ferrand, France

[3] Hop St Louis, Serv Hematol Greffe, F-75010 Paris, France

[4] Ctr Jean Perrin, Serv Radiotherapie, F-63000 Clermont Ferrand, France

来源：

BULLETIN DU CANCER | 2013年 / 100卷 / 06期

关键词：

cancer; chemotherapy; targeted therapies; allo-graft; perspective; retrospective; CHRONIC LYMPHOCYTIC-LEUKEMIA; EXTENDED-FIELD RADIOTHERAPY; BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; ACUTE MYELOID-LEUKEMIA; ABL TYROSINE KINASE; HODGKINS-LYMPHOMA; COMBINATION CHEMOTHERAPY; RADIATION-THERAPY; BODY IRRADIATION;

D O I：

10.1684/bdc.2013.1751

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hematology Oncology has a rich history including few crucial therapeutic innovations. These were possible because of the evolution of the cell and molecular biology allowing a better understanding of basic mechanisms of cancerogenesis. We propose here to summarize the most important therapeutic innovations since the beginning of Hematology/Oncology history. We also describe evolution of therapeutic strategies themselves. New insights and therapeutic perspectives for next future are also discussed.

引用

页码：587 / 599

页数：13

共 92 条

[1] TREATMENT FOR MULTIPLE MYELOMA - COMBINATION CHEMOTHERAPY WITH DIFFERENT MELPHALAN DOSE REGIMENS [J].

ALEXANIAN, R ;

HAUT, A ;

KHAN, AU ;

LANE, M ;

MCKELVEY, EM ;

MIGLIORE, PJ ;

STUCKEY, WJ ;

WILSON, HE .

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1969, 208 (09) :1680-+

[2]

Andre MP, 2009, ASH ANN M, V114, P97

[3] NEUROPHARMACOLOGY OF EMESIS INDUCED BY ANTI-CANCER THERAPY [J].

ANDREWS, PLR ;

RAPEPORT, WG ;

SANGER, GJ .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1988, 9 (09) :334-341

[4] Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia [J].

Badoux, Xavier C. ;

Keating, Michael J. ;

Wang, Xuemei ;

O'Brien, Susan M. ;

Ferrajoli, Alessandra ;

Faderl, Stefan ;

Burger, Jan ;

Koller, Charles ;

Lerner, Susan ;

Kantarjian, Hagop ;

Wierda, William G. .

BLOOD, 2011, 118 (08) :2085-2093

[5] TREATMENT OF MURINE LEUKAEMIA WITH X-RAYS AND HOMOLOGOUS BONE MARROW - PRELIMINARY COMMUNICATION [J].

BARNES, DWH ;

CORP, MJ ;

LOUTIT, JF ;

NEAL, FE .

BRITISH MEDICAL JOURNAL, 1956, 2 (SEP15) :626-627

[6]

BERNARD J, 1959, Schweiz Med Wochenschr, V89, P604

[7]

BERNARD J, 1972, NOUV PRESSE MED, V1, P2149

[8] ACUTE PROMYELOCYTIC LEUKEMIA - RESULTS OF TREATMENT BY DAUNORUBICIN [J].

BERNARD, J ;

WEIL, M ;

BOIRON, M ;

JACQUILLAT, C ;

FLANDRIN, G ;

GEMON, MF .

BLOOD, 1973, 41 (04) :489-496

[9] STRATEGIES IN PREVENTION OF INVASIVE PULMONARY ASPERGILLOSIS IN IMMUNOSUPPRESSED OR NEUTROPENIC PATIENTS [J].

BEYER, J ;

SCHWARTZ, S ;

HEINEMANN, V ;

SIEGERT, W .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (05) :911-917

[10]

BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO

← 1 2 3 4 5 6 7 8 9 10 →